Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) announced completion of oral dosing in both 180-day repeated-dose toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS). These chronic studies are described as supporting an Investigational New Drug (IND) application with the US FDA and informing the design of a Phase 2 trial in people with multiple sclerosis (MS). Company executives said study completion advances the Lucid-MS development program and moves the program closer to initiating a Phase 2 trial targeting prevention of disease progression and inhibition of demyelination in MS.
Quantum BioPharma (NASDAQ: QNTM) closed a non-brokered private placement on December 10, 2025, issuing 30 Class A multiple voting shares at $25 per share for gross proceeds of $750. Two related parties — Xorax Family Trust and Fortius Research and Trading — each bought 15 Class A shares, triggering MI 61-101 and early warning disclosures under NI 62-103.
Following the offering, Xorax's voting rights rose to 37.66% and Fortius' to 37.63%. The company also terminated its at-the-market sales agreement with H.C. Wainwright effective Dec 20, 2025, and settled $260,000 of debt by issuing 17,626 Class B subordinate voting shares at a deemed price of $14.75 per share.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 30, 2025 at 4:15 PM EST (1:15 PM PST) to discuss a Regulation D 506(c) offering targeting US$5.0 million to expand distribution of unbuzzd, a beverage the company says accelerates alcohol metabolism and reduces hangover symptoms. The release states that Quantum shareholders will not be diluted by this offering and that the offering is for accredited investors only. Webinar speakers include Unbuzzd CEO John Duffy, Medical Director Dr. Eric Hoskins, Advisor Jason Sawyer, and Board Co-Chair Gerry David. A replay is available on request via investor@unbuzzd.com.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
